SomnoMedSOMNF 51 9-Day RSI is 0.01 as of Jul. 07, 2026. GuruFocus rates SOMNF with a GF Score™ of 51/100 and a GF Value™ of $0.40. The stock has 3 warning signs investors should review. Among 869 Medical Devices & Instruments companies, SomnoMed ranks better than 51.55% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-07), SomnoMed's 9-Day RSI is 0.01.
The industry rank for SomnoMed's 9-Day RSI or its related term are showing as below:
SOMNF's 9-Day RSI is ranked better than 51.55% of 869
companies
in the Medical Devices & Instruments industry
Industry Median: 52.68
vs SOMNF: 0.01
SomnoMed (OTCPK:SOMNF) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
SomnoMed 9-Day RSI Related Terms
SOMNF vs ABT, SYK, MDT: 9-Day RSI Comparison
For the Medical Devices subindustry, SomnoMed's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SomnoMed 9-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SomnoMed's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where SomnoMed's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SomnoMed (SOMNF) has a 9-Day RSI of 0.01 as of Jul. 07, 2026. According to the industry distribution chart, SomnoMed ranks #421 out of 869 companies in the Medical Devices & Instruments industry, placing it in the top 48.4%.
Is SomnoMed's 9-Day RSI too high?
SomnoMed's current 9-Day RSI is 0.01. The Medical Devices & Instruments industry median 9-Day RSI is 52.68. SomnoMed's value of 0.01 is 100% below this industry median. Based on the distribution chart, SomnoMed ranks #421 out of 869 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, SomnoMed has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does SomnoMed's 9-Day RSI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, SomnoMed ranks #421 out of 869 companies for 9-Day RSI. This puts SomnoMed in the upper half of its industry. The industry median 9-Day RSI is 52.68. SomnoMed's value of 0.01 is 100% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Devices & Instruments company?
The median 9-Day RSI among Medical Devices & Instruments companies is 52.68, based on 869 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SomnoMed's current 9-Day RSI of 0.01 is 100% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median 9-Day RSI is 52.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SomnoMed's current 9-Day RSI is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SomnoMed stock overvalued right now?
SomnoMed (SOMNF) has a current 9-Day RSI of 0.01. The stock's GF Value™ is $0.40, compared to a current price of $0.45 — trading 12% above its estimated fair value. The current 9-Day RSI is 0.01 and 100% below the Medical Devices & Instruments industry median of 52.68. SomnoMed's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For SomnoMed (SOMNF), the current 9-Day RSI is 0.01 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SomnoMed (SOMNF) Overvalued in 2026?
Based on GuruFocus' analysis, SomnoMed stock appears to be overvalued.
The current stock price of $0.45 is trading 12% above its estimated GF Value™ of $0.40.
Key valuation signals for SOMNF:
9-Day RSI: 0.01
GF Value™: $0.40 vs. price of $0.45 (12% above fair value)
Industry Position: 100% below the Medical Devices & Instruments median (#421 of 869)
No single metric tells the full story. See the SOMNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SomnoMed Ltd provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is engaged in commercializing SomnoDent Mandibular Advancement Splint (MAS) and other oral devices for sleep-related disorders in Australia and overseas. The other products in the company's portfolio include SomMorning Repositioner; SomnoBrux splint, a custom-fit, acrylic splint (dental guard) for upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs cleaning tablets that have been developed to clean oral appliances. Geographically, the company generates maximum revenue from Europe, followed by North America and the Asia Pacific region.
51GF Score
Get the complete analysis for SOMNF
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SOMNF has been successfully added to your 